Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Income Before Tax

Profit after all operating and non-operating items but before income tax.

Upstream Bio, Inc.NASDAQ: UPB

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$40.59M, compared with -$27.27M a year earlier. Trailing-twelve-month income before tax was -$156.76M.

Context

  • Income before tax amounted to 5026.0% of revenue in FY2025, up 2376.0 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$40.59M or moves back toward the trailing-twelve-month quarterly average of -$39.19M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$40.59M+4.4% QoQ
Last fiscal yearDec 2025
-$143.44M-128.4% YoY
LTMMar 2026
-$156.76M-98.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-48.8%——
1 year-128.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(143.44M) USD
Year-over-year change
-128.4%

Income Before Tax vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -98.0% is the 8th highest of 10, against a peer median of -8.9%.
  • Income before tax amounts to 4719.0% of revenue for UPB, versus a peer median of 273.6%.
UPB Competitors
Income Before Tax for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVAXNovavax, Inc.LTM Mar 2026-$86.19M USD-117.6%—14.5%
UPBUpstream Bio, Inc.LTM Mar 2026-$156.76M USD-98.0%—4719.0%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026-$163.15M USD-8.8%——
PHVSPharvaris N.V.LTM Sep 2026-€179.08M EUR-8.9%——
WVEWave Life Sciences Ltd.LTM Mar 2026-$183.59M USD-63.4%—255.7%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-$243.25M USD+26.6%—112.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026-$263.86M USD-77.1%—291.6%
RLAYRelay Therapeutics, Inc.LTM Jun 2026-$286.04M USD+8.2%—2763.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$394.6M USD+25.0%—597.0%
ZBIOZenas BioPharma, Inc.LTM Mar 2026-$425.03M USD-161.5%——
Peer median (excluding UPB) —-8.9%—273.6%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.